欢迎来到范德生物BIOFOUNT
范德生物中国

中文范德生物中文语言

范德生物产品购买购物车
0
搜索
Natalizumab_189261-10-7_产品详情
189261-10-7
  • names:

    Natalizumab

  • CAS号:

    189261-10-7

    MDL Number:
  • MF(分子式): MW(分子量):
  • EINECS: Reaxys Number:
  • Pubchem ID: Brand:BIOFOUNT
Natalizumab
货品编码 规格 纯度 价格 (¥) 现价(¥) 特价(¥) 库存描述 数量 总计 (¥)
YZM002829-250mg 250mg ¥ 0.00 ¥ 0.00 Backorder
- +
¥ 0.00
YZM002829-100mg 100mg >97% ¥ 0.00 ¥ 0.00 2-3天
- +
¥ 0.00
快速询价
收起
你想询价的产品
请准确填写您的联系方式,以便为您提供最好的服务。
中文别名
英文别名
CAS号 189261-10-7
Inchi
InchiKey
分子式 Formula
分子量 Molecular Weight
溶解度Solubility
性状
储藏条件 Storage conditions 请根据产品建议的存储条件进行存储,Please store the product under the recommended condition sin the description.
Natalizumab(CAS:189261-10-7)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
产品说明 Natalizumab 是一种有效的重组的人源化单克隆抗体,与 α4β1-整联蛋白 (α4β1-integrin) 结合并阻断其与血管细胞粘附分子 1 (VCAM-1) 的相互作用
IntroductionNatalizumab is a recombinant, humanized monoclonal antibody, binds to α4β1ntegrinand blocks its interaction with vascular cell adhesion molecule (VCAM). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses.
Application1
Application2
Application3
Natalizumab 是一种有效的重组的人源化单克隆抗体,与 α4β1-整联蛋白 (α4β1-integrin) 结合并阻断其与血管细胞粘附分子 1 (VCAM-1) 的相互作用。Natalizumab 可用于治疗复发缓解型多发性硬化症和克罗恩氏病。Natalizumab 也可阻止淋巴细胞进入中枢神经系统,从而防止急性脱髓鞘复发。Natalizumab is a recombinant, humanized monoclonal antibody, binds to α4β1-integrinand blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses[1].
警示图
危险性
危险性警示
安全声明
安全防护
备注
【1】.Hutchinson M. Natalizumab: A new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2007 Jun;3(2):259-68.
    对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
        新闻
        抱歉,暂无数据!
        My title page contents